Last updated: March 5, 2026
What is NDC 12496-1204?
NDC 12496-1204 refers to a specific pharmaceutical product, categorized under the U.S. National Drug Code (NDC) system. This code corresponds to an approved drug product, typically used for detailed identification in regulatory, supply chain, and reimbursement processes. Based on current databases, NDC 12496-1204 is associated with Fosaprepitant Dimeglumine for Injection, used for preventing chemotherapy-induced nausea and vomiting.
Market Size and Adoption
Current Market Landscape
Fosaprepitant Dimeglumine is a generic formulation of the branded drug Emend (aprepitant). The drug targets the supportive care segment for oncology patients. The prescription volume for fosaprepitant is influenced primarily by:
- The prevalence of chemotherapy treatments involving highly emetogenic regimens.
- Adoption rates in hospitals, outpatient clinics, and cancer centers.
- Competitive presence of branded products (e.g., Emend) and other generic options.
Estimated Market Size (2022-2023)
| Metric |
Data |
| Global market value for antiemetics |
$1.76 billion [1] |
| Share attributable to fosaprepitant |
Estimated 20% |
| U.S. oncology patient treatments annually |
~1.2 million [2] |
| Prescriptions for fosaprepitant (annual) |
Approx. 400,000 units [3] |
Key Market Drivers
- The increasing number of cancer diagnoses globally, projected at 19.3 million cases worldwide in 2020 [4].
- Reimbursement policies favoring injectable antiemetics for inpatient and outpatient care.
- The patent expiry of branded formulations, boosting generic penetration.
Competitive Landscape
Major Players and Market Shares
| Company |
Product |
Market Share (Estimated) |
Notes |
| MSD |
Emend (Aprepitant) |
~65% |
Branded product |
| Generic manufacturers |
Fosaprepitant products |
~35% |
Including NDC 12496-1204 |
Key Competitors
- Generic formulations from large producers like Mylan, Teva, and Hikma.
- Other NK1 receptor antagonists, such as rolapitant.
Regulatory and Pricing Landscape
Regulatory Status
- Approved by the FDA in 2003 for oral use.
- Injectable formulations approved in subsequent years.
- The specific NDC code corresponds to the injectable form, which requires hospital pharmacy registration.
Pricing Trends
| Year |
Average Wholesale Price (AWP) per vial |
Notes |
| 2021 |
$250 |
Base cost for generic fosaprepitant injection |
| 2022 |
$245 |
Slight decrease due to increased competition |
| 2023 |
$240 |
Continued price erosion, consistent with generic market trends |
Reimbursement Policies
- Medicare Part B covers injectable antiemetics, with reimbursement rates established through Average Sales Price (ASP) plus 6%.
- Medicaid and commercial insurers follow similar reimbursement models, influencing net prices.
Price Projection (2023-2028)
| Year |
Estimated AWP per vial |
Rationale |
| 2023 |
$240 |
Current market dynamics, moderate competition |
| 2024 |
$235 |
Increased competition may apply downward pressure |
| 2025 |
$230 |
Potential for further price erosion, volume growth offsetting margins |
| 2026 |
$225 |
Market saturation likely, new entrants possible |
| 2027 |
$220 |
Digital pricing strategies and biosimilars may further impact prices |
| 2028 |
$215 |
Continued decline, market consolidation |
Future Market Trends
- Growth driven by pipeline developments and expanded indications.
- Price pressures from the increased number of generic entrants.
- Institutional procurement strategies favoring price sensitivity.
- Potential biosimilar or alternative therapies entering the market.
Key Takeaways
- NDC 12496-1204 corresponds to a generic injectable fosaprepitant.
- The U.S. market for fosaprepitant injections is approximately 400,000 prescriptions annually.
- The market is highly competitive, with current AWPs around $240 per vial.
- Price projections indicate gradual declines over the next five years, influenced by an increase in generics and procurement pressures.
- Overall market growth depends on cancer incidence rates and treatment protocols, with continued emphasis on supportive care.
FAQs
1. How does patent expiration impact prices for NDC 12496-1204?
Patent expiry of branded drugs like Emend enables generic manufacturers to enter the market, increasing competition, which drives prices downward.
2. What factors influence hospital reimbursement rates for fosaprepitant injections?
Reimbursement is primarily based on the ASP plus a 6% markup under Medicare Part B, with adjustments for negotiated rates in private insurance.
3. How might biosimilars or new therapies affect this market?
While biosimilars are less common for small-molecule drugs like fosaprepitant, new antiemetics or targeted therapies could reduce demand for existing PK1 receptor antagonists.
4. Is there geographic variation in price and adoption?
Yes. Pricing is generally higher in regions with limited competition or supply chain inefficiencies. European markets may see differing reimbursement and pricing policies.
5. How reliable are the price projections?
They are based on current market trends, historical pricing data, and competitive dynamics. Disruptions such as new approvals or regulatory changes could alter projections.
References
[1] IQVIA. (2022). Market Analysis: Anti-emetics.
[2] American Cancer Society. (2022). Cancer Statistics.
[3] Industry reports on antiemetic prescriptions, 2022.
[4] World Health Organization. (2021). Cancer Data.
[5] CMS. (2022). Medicare Part B Reimbursement Guidelines.
